OPEN ACCESS

Saudi Journal of Nursing and Health Care
Abbreviated Key Title: Saudi J Nurs Health Care
ISSN 2616-7921 (Print) | ISSN 2616-6186 (Online)
Scholars Middle East Publishers, Dubai, United Arab Emirates
Journal homepage: https://saudijournals.com

Review Article

Advancements in HPV Vaccination for Cervical Cancer Prevention: A Comprehensive Review

Keerti Halemani[1*], Sannamma H J[2]

[1]PG Nursing Tutor, BLDEA'S College of Nursing, Jamkhandi, Karnataka, India
[2]Assistant Professor, Govt. College of Nursing, Vijayapura, Karnataka, India

DOI: 10.36348/sjnhc.2024.v07i05.002 | **Received:** 02.04.2024 | **Accepted:** 06.05.2024 | **Published:** 10.05.2024

***Corresponding author:** Keerti Halemani
PG Nursing Tutor, BLDEA'S College of Nursing, Jamkhandi, Karnataka, India

Abstract

Cervical cancer remains a significant global health challenge, particularly in less developed regions, despite advancements in prevention and treatment. The World Health Organization (WHO) has prioritized vaccination as a key strategy for cervical cancer elimination. However, limited vaccine coverage persists, especially in countries like India and China. In India, cervical cancer is a leading cause of female mortality, highlighting the urgent need for population-based interventions. Human papillomavirus (HPV) is the primary causative agent, with HPV-16 and 18 being prevalent in Indian women. Since its recommendation in 2006, the HPV vaccine has shown remarkable efficacy, with the potential to prevent over 90% of HPV-attributable cancers. Recent advancements include the development of single-dose vaccines, offering a cost-effective solution to enhance accessibility. Democratizing access to vaccines is crucial for achieving WHO's goals of cervical cancer elimination.

Keywords: HPV vaccine, cervical cancer prevention, HPV types, vaccine efficacy, recent updates, vaccine accessibility.

INTRODUCTION

Cervical cancer poses a significant global health challenge, particularly in less developed regions, despite advancements in prevention and treatment. The World Health Organization (WHO) has identified vaccination as a critical strategy for cervical cancer elimination. However, limited vaccine coverage persists, especially in countries like India and China, hindering global efforts. In India, where cervical cancer is a leading cause of female mortality, targeted interventions are urgently needed. Human papillomavirus (HPV), notably types 16 and 18, plays a pivotal role in cervical carcinogenesis, underscoring the importance of HPV vaccination in prevention strategies. This comprehensive review examines recent advancements in HPV vaccination for cervical cancer prevention, emphasizing the significance of equitable vaccine access and delivery.

Disease Spectrum:

HPV, a member of the Papillomaviridae family, comprises over 100 serotypes, with 15-20 being oncogenic. The lag period between HPV infection and invasive cervical cancer is approximately 15-20 years. In Indian women, HPV-16 and 18 are prevalent oncogenic genotypes. Non-oncogenic types like HPV-6 and 11 contribute to benign genital infections such as genital warts.

HPV Vaccine:

HPV vaccination has demonstrated remarkable efficacy in preventing HPV-attributable cancers since its introduction in 2006. Infections with HPV types causing most HPV cancers and genital warts have significantly declined among vaccinated populations. Recent studies have highlighted the long-term efficacy and safety of HPV vaccines, reinforcing their role in cervical cancer prevention.

Vaccine Types:

Several HPV vaccines, including Cervarix, Gardasil, Gardasil 9, and India's indigenous Cervavac, offer comprehensive protection against HPV-related diseases. Each vaccine targets specific HPV types,

contributing to the prevention of cervical cancer, genital warts, and other HPV-associated cancers.

Efficacy:

The HPV vaccine effectively targets HPV types causing cervical cancer, as well as other cancers of the vulva, vagina, anus, and oropharynx. It also protects against the HPV types responsible for most genital warts. While highly effective in preventing targeted HPV types, its efficacy may be reduced in individuals already exposed to HPV.

Recent Updates:

Recent advancements in HPV vaccination include the development of single-dose vaccines, offering a promising solution to enhance vaccine accessibility and administration, particularly in resource-limited settings.

Adverse Effects:

Common side effects of HPV vaccination include pain and swelling at the injection site, headache, fever, and vomiting. These adverse effects are generally mild and transient.

Beneficiaries and Accessibility:

HPV vaccination is recommended for girls aged 11-12, with catch-up vaccination available for girls aged 9 and above. Teens and young adults up to age 26 who haven't completed the vaccine series can also receive vaccination. Ensuring equitable access to HPV vaccines requires political commitment and streamlined vaccination programs.

CONCLUSION

HPV vaccination has emerged as a potent tool in cervical cancer prevention, with substantial reductions in HPV infections and associated diseases observed worldwide. However, challenges in vaccine accessibility and administration persist, necessitating ongoing efforts to democratize access to vaccines. Achieving WHO's vision of cervical cancer elimination requires sustained commitment from governments, healthcare providers, researchers, and civil society to prioritize evidence-based vaccination programs and address barriers to vaccine uptake. By fostering collaboration and innovation in vaccine delivery, we can advance towards the goal of eliminating cervical cancer and improving women's health globally.

REFERENCES

- Brisson, M., Kim, J. J., Canfell, K., Drolet, M., Gingras, G., Burger, E. A., ... & Hutubessy, R. (2020). Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. *The Lancet*, *395*(10224), 575-590. doi: 10.1016/S0140-6736(20)30068-4.
- International Agency for Research on Cancer, World Health Organization. Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Lyon. 2012.
- Kaarthigeyan, K. (2012). Cervical cancer in India and HPV vaccination. *Indian J Med Paediatr Oncol*, *33*(1), 7-12. doi: 10.4103/0971-5851.96961. PMID: 22754202; PMCID: PMC3385284.
- Sankaranarayanan, R., Bhatla, N., Gravitt, P. E., Basu, P., Esmy, P. O., Ashrafunnessa, K. S., ... & Nene, B. M. (2008). Human papillomavirus infection and cervical cancer prevention in India, Bangladesh, Sri Lanka and Nepal. *Vaccine*, *26*, M43-M52.